KPX Lifescience.Co.Ltd Cash Flow Conversion Efficiency
KPX Lifescience.Co.Ltd cash flow conversion efficiency. Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) has a cash flow conversion efficiency ratio of 0.095x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.33 Billion ≈ $2.26 Million USD) by net assets (₩35.13 Billion ≈ $23.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of KPX Lifescience.Co.Ltd (2014–2024)
Cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024. This chart illustrates how KPX Lifescience.Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 114450 share price today for real-time trading data and today's change.
KPX Lifescience.Co.Ltd Cash Flow Conversion Ratio Explained
KPX Lifescience.Co.Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
KPX Lifescience.Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KPX Lifescience.Co.Ltd ranked by their cash flow conversion efficiency. Also see how much is KPX Lifescience.Co.Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dayou AP Co.Ltd
KQ:290120
|
0.083x |
|
EL. D. Mouzakis S.A
AT:MOYZK
|
0.002x |
|
Astral Asia Bhd
KLSE:7054
|
0.003x |
|
Retractable Technologies Inc
NYSE MKT:RVP
|
-0.008x |
|
Phol Dhanya Public Company Limited
BK:PHOL
|
0.109x |
|
Mountain Alliance AG
XETRA:ECF
|
-0.020x |
|
Cruzados SADP
SN:CRUZADOS
|
-0.021x |
|
Kumbi Corporation
KO:008870
|
0.059x |
Annual Cash Flow Conversion Efficiency for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of KPX Lifescience.Co.Ltd from 2014 to 2024. Review 114450 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩35.75 Billion ≈ $24.23 Million |
₩525.49 Million ≈ $356.12K |
0.015x | +42.84% |
| 2023-12-31 | ₩35.95 Billion ≈ $24.37 Million |
₩370.02 Million ≈ $250.76K |
0.010x | +111.90% |
| 2022-12-31 | ₩52.64 Billion ≈ $35.67 Million |
₩-4.55 Billion ≈ $-3.08 Million |
-0.086x | -896.27% |
| 2021-12-31 | ₩56.30 Billion ≈ $38.15 Million |
₩611.38 Million ≈ $414.33K |
0.011x | -66.11% |
| 2020-12-31 | ₩59.37 Billion ≈ $40.23 Million |
₩1.90 Billion ≈ $1.29 Million |
0.032x | -54.41% |
| 2019-12-31 | ₩60.36 Billion ≈ $40.90 Million |
₩4.24 Billion ≈ $2.87 Million |
0.070x | -22.75% |
| 2018-12-31 | ₩59.11 Billion ≈ $40.06 Million |
₩5.38 Billion ≈ $3.64 Million |
0.091x | -0.57% |
| 2017-12-31 | ₩62.09 Billion ≈ $42.08 Million |
₩5.68 Billion ≈ $3.85 Million |
0.091x | -20.17% |
| 2016-12-31 | ₩61.66 Billion ≈ $41.79 Million |
₩7.07 Billion ≈ $4.79 Million |
0.115x | +16.09% |
| 2015-12-31 | ₩56.90 Billion ≈ $38.56 Million |
₩5.62 Billion ≈ $3.81 Million |
0.099x | +24.53% |
| 2014-12-31 | ₩51.53 Billion ≈ $34.92 Million |
₩4.09 Billion ≈ $2.77 Million |
0.079x | -- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more